Ascend Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Ascend Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-176,353	Closed	-$3.43M	–	255
2018 Q1	$3.43M	Buy	+176,353	New	+$3.46M	0.14%	138
2014 Q3	–	Sell	-25,000	Closed	-$750K	–	228
2014 Q2	$750K	Sell	25,000 -81,132	-76%	-$2.19M	0.03%	161
2014 Q1	$2.8M	Sell	106,132 -43,952	-29%	-$1.1M	0.07%	165
2013 Q4	$3.77M	Sell	150,084 -1,045,960	-87%	-$23.3M	0.11%	146
2013 Q3	$24.5M	Sell	1,196,044 -108,432	-8%	-$2.24M	0.91%	31
2013 Q2	$26M	Buy	+1,304,476	New	+$23.2M	1.11%	25

Ascend Capital's IPXL Position: Q2 2018 in Review

Ascend Capital sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 176,353 shares — an estimated $3.43M sold.

Ascend Capital first reported a position in IPXL in Q2 2013 and held it in 6 quarters. The position peaked at $26M in Q2 2013. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Ascend Capital reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 176,353 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3.43M.
Ascend Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 6 quarters.
Ascend Capital's Impax Laboratories, Inc. position peaked at $26M in Q2 2013.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.